Literature DB >> 31699325

Prion-like propagation of α-synuclein in neurodegenerative diseases.

Airi Tarutani1, Masato Hasegawa2.   

Abstract

Prions are defined as proteinaceous infectious particles that do not contain nucleic acids. Neuropathological investigations of post-mortem brains and recent studies of experimental transmission have suggested that amyloid-like abnormal protein aggregates, which are the defining feature of many neurodegenerative diseases, behave like prions and propagate throughout the brain. This prion-like propagation may be the underlying mechanism of onset and progression of neurodegenerative diseases, although the precise molecular mechanisms involved remain unclear. However, in vitro and in vivo experimental models of prion-like propagation using pathogenic protein seeds are well established and are extremely valuable for the exploration and evaluation of novel drugs and therapies for neurodegenerative diseases for which there is no effective treatment. In this chapter, we introduce the experimental models of prion-like propagation of α-synuclein, which is accumulated in Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, and we describe their applications for the development of new diagnostic and therapeutic modalities. We also introduce the concept of "α-syn strains," which may underlie the pathological and clinical diversity of α-synucleinopathies.
© 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell-to-cell transmission; Neurodegenerative diseases; Prion; Strains; α-Synuclein; α-Synucleinopathies

Mesh:

Substances:

Year:  2019        PMID: 31699325     DOI: 10.1016/bs.pmbts.2019.07.005

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  9 in total

Review 1.  Application of yeast to studying amyloid and prion diseases.

Authors:  Yury O Chernoff; Anastasia V Grizel; Aleksandr A Rubel; Andrew A Zelinsky; Pavithra Chandramowlishwaran; Tatiana A Chernova
Journal:  Adv Genet       Date:  2020-05-04       Impact factor: 1.944

2.  Electron Microscopic Analysis of α-Synuclein Fibrils.

Authors:  Airi Tarutani; Masato Hasegawa
Journal:  Methods Mol Biol       Date:  2021

3.  LMTK1, a Novel Modulator of Endosomal Trafficking in Neurons.

Authors:  Shin-Ichi Hisanaga; Ran Wei; Anni Huo; Mineko Tomomura
Journal:  Front Mol Neurosci       Date:  2020-06-30       Impact factor: 5.639

4.  Genetic prion disease: D178N with 129MV disease modifying polymorphism-a clinical phenotype.

Authors:  Tracie Huey-Lin Tan; Richard J Stark; John A Waterston; Owen White; Dominic Thyagarajan; Mastura Monif
Journal:  BMJ Neurol Open       Date:  2020-09-18

5.  Voxel-Based Meta-Analysis of Gray Matter Abnormalities in Multiple System Atrophy.

Authors:  Junyu Lin; Xinran Xu; Yanbing Hou; Jing Yang; Huifang Shang
Journal:  Front Aging Neurosci       Date:  2020-11-27       Impact factor: 5.750

Review 6.  Extracellular Vesicles Physiological Role and the Particular Case of Disease-Spreading Mechanisms in Polyglutamine Diseases.

Authors:  Ricardo Moreira; Liliana S Mendonça; Luís Pereira de Almeida
Journal:  Int J Mol Sci       Date:  2021-11-13       Impact factor: 5.923

7.  Deficient immunoproteasome assembly drives gain of α-synuclein pathology in Parkinson's disease.

Authors:  Mingxia Bi; Xixun Du; Xue Xiao; Yingying Dai; Qian Jiao; Xi Chen; Lingqiang Zhang; Hong Jiang
Journal:  Redox Biol       Date:  2021-10-14       Impact factor: 11.799

Review 8.  Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson's disease.

Authors:  Nouara Yahi; Coralie Di Scala; Henri Chahinian; Jacques Fantini
Journal:  Glycoconj J       Date:  2021-07-30       Impact factor: 2.916

Review 9.  The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson's Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline.

Authors:  Per Borghammer
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.